Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) EBITDA (2016 - 2025)

Historic EBITDA for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to $2.0 million.

  • OptimizeRx's EBITDA rose 12394.3% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 12393.16%. This contributed to the annual value of -$13.6 million for FY2024, which is 4831.19% up from last year.
  • According to the latest figures from Q3 2025, OptimizeRx's EBITDA is $2.0 million, which was up 12394.3% from $3.2 million recorded in Q2 2025.
  • OptimizeRx's EBITDA's 5-year high stood at $3.6 million during Q4 2024, with a 5-year trough of -$10.9 million in Q4 2023.
  • Its 5-year average for EBITDA is -$2.6 million, with a median of -$3.6 million in 2023.
  • Per our database at Business Quant, OptimizeRx's EBITDA crashed by 993702.28% in 2022 and then soared by 18506.27% in 2025.
  • Quarter analysis of 5 years shows OptimizeRx's EBITDA stood at $621080.0 in 2021, then tumbled by 239.17% to -$864348.0 in 2022, then crashed by 1161.41% to -$10.9 million in 2023, then soared by 133.33% to $3.6 million in 2024, then plummeted by 43.59% to $2.0 million in 2025.
  • Its EBITDA was $2.0 million in Q3 2025, compared to $3.2 million in Q2 2025 and -$2.1 million in Q1 2025.